Motor Neuron Disease clinical trials

The registry lists 203 studies for Motor Neuron Disease across more than 10 countries. 61 are recruiting or about to start. 27 of them are mainly about Motor Neuron Disease (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-12. Counting its 4 narrower conditions too, such as Amyotrophic Lateral Sclerosis: 1,357 studies, 376 open.

Get an email when these change. Save the Motor Neuron Disease studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies

See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed: 95
Recruiting: 43
Terminated: 16
Active, not recruiting: 13
Not yet recruiting: 12
Status unknown: 10

Phase

Phase 2: 38
Phase 1: 25
Phase 3: 12
Phase 4: 2
Early Phase 1: 1

Where

United States: 107
United Kingdom: 24
Italy: 17
France: 17
Canada: 17
Australia: 16

Who runs them

National Institute of Neurological Disorders and Stroke (NINDS) (20) · Drexel University College of Medicine (9) · University of Miami (5) · University of Alberta (5) · Columbia University (4) · Knopp Biosciences (4) · Nova Southeastern University (3) · Synchron, Inc. (3)

What is being tested here

Drugs under test in Motor Neuron Disease studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug	Open	Phase 3	All
Riluzole	1	0	1
Anti-CD20 Antibody-drug Conjugate MRG001	1	0	1
Acamprosate	1	0	1
Ranolazine	1	0	1
Masitinib	1	1	1
Dexpramipexole	0	2	4
Immunoglobulins, Intravenous	0	1	2
Immunoglobulin G	0	1	2
Sodium phenylbutyrate and taurursodiol	0	0	2
Atibuclimab	0	0	2

Coming up

1phase 3 study under way

21studies finish main data collection within a year

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest

Nov 2026UAE-PRIME: A Feasibility Study of a Precise Robotically Implanted Brain-Computer Interface for the Control of External Devices · Neuralink Corp
Nov 2026Intravenous Immunoglobulin (IVIG) and Blood-Brain Barrier Disruption in Amyotrophic Lateral Sclerosis (ALS) · Sunnybrook Health Sciences Centre
Dec 2026Impact of Physical Functioning on Patient-Reported Outcomes in ALS Patients at TidalHealth · TidalHealth, Inc.
Dec 2026Clinical, Molecular and Imaging Biomarkers in Spinal and Bulbar Muscular Atrophy (SBMA) · National Institute of Neurological Disorders and Stroke (NINDS)
Dec 2026The Study Evaluating the Improvement of Nutritional Status and Frailty With Silkworm Pupa Powder Among Patients With Motor Neuron Disease · First People's Hospital of Hangzhou
Dec 2026Creation of a Clinical Database for the Study of Phenotypic Variability in Motor Neuron Diseases · Istituto Auxologico Italiano
Jan 2027INdependence Through Endovascular Neuroprosthetic Technology (INTENT): an Early Feasibility Study · Synchron, Inc.
Jan 2027Validation of the French Version of the Primary Lateral Sclerosis Functioning Rating Scale (PLSFRS) · University Hospital, Tours
Jan 2027Kamlanoflast In Amyotrophic Lateral Sclerosis · Inflammasome Therapeutics
Jan 2027Impact of Robotic Glove Use on Quality of Life, Grip Strength and Fine Motor Control in ALS · Nova Southeastern University

Who these studies take

Of the 43 Motor Neuron Disease studies recruiting now, 29 (67%) set no upper age limit and 2 (5%) stop at 75 or younger. 10 (23%) take children under 18. 0 (0%) are for women only and 1 (2%) for men only; 16 (37%) take healthy volunteers.

Recruiting studies that take each age, of 43
Age	Women	Men
10	9 (21%)	9 (21%)
18	41 (95%)	42 (98%)
30	42 (98%)	43 (100%)
40	41 (95%)	42 (98%)
50	41 (95%)	42 (98%)
65	41 (95%)	42 (98%)
75	41 (95%)	42 (98%)
85	35 (81%)	36 (84%)

Across all 203 studies, recruiting or not: 12% stop at 75 or younger and 1% at 65; 15% take children; 0% are for women only and 2% for men only; 25% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Motor Neuron Disease studies take

Of 11 phase 2 interventional studies under Motor Neuron Disease, half reached primary completion within 22 months of starting, counting those still running.

Start to primary completion	Every sponsor	Industry	Non-industry
Phase 2	22 mo15–27 · 11 studies	—	—
Interventional, no phase	35 mo11–77 · 32 studies	—	—
Observational	88 mo57–… · 42 studies	—	—

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 13, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 203. Browse all 203 → or search them.